News | May 07, 2026
Novo Nordisk posts strong Q1 as Wegovy drives global GLP-1 momentum
The standout story remains Wegovy, particularly its new oral formulation
The standout story remains Wegovy, particularly its new oral formulation
The study evaluated oral semaglutide in young patients with type 2 diabetes and found it delivered a superior reduction in HbA1c
By cutting pain crises & boosting haemoglobin
The collaboration will embed OpenAI’s advanced AI systems across Novo Nordisk’s global operations
The trial demonstrated that immune responses in children were non-inferior to adults, with a similar safety profile after two standard doses of MVA-BN
Price of the starting dose of Ozempic and Wegovy reduced by 36% and 48% respectively
The initiative will focus on creating healthier early-life environments, promoting physical activity, identifying risks early, and strengthening preparedness within primary health care systems
Under the deal, Hims & Hers will offer patients access to FDA-approved versions of Ozempic and Wegovy at the same self-pay prices available through other telehealth platforms
The construction projects, which have already begun, will be finalised gradually from the end of 2027 through 202
Under the deal, Vivtex will license select oral drug-delivery technologies to Novo Nordisk
Subscribe To Our Newsletter & Stay Updated
